# MSI2

## Overview
Musashi RNA binding protein 2 (MSI2) is a gene that encodes an RNA-binding protein involved in the regulation of stem cell function and differentiation. The MSI2 protein is categorized as an RNA-binding protein, playing a pivotal role in post-transcriptional regulation by interacting with the 3'-untranslated regions (3'-UTRs) of target mRNAs. This interaction influences mRNA translation, stability, and turnover, which is crucial for maintaining the balance between self-renewal and differentiation in stem cells (das2020Interplay). MSI2 is expressed in various tissues, including bone marrow stromal cells and neural precursor cells, where it regulates differentiation and maintains specific cell lineages (Suo2022The; Sakakibara2001RNA-Binding). Dysregulation of MSI2 expression has been implicated in several cancers, where it often correlates with poor prognosis and increased tumor aggressiveness (Wang2015Transformation; Kudinov2016Musashi2).

## Function
Musashi RNA binding protein 2 (MSI2) is an RNA-binding protein that plays a critical role in the regulation of stem cell function and differentiation. In healthy human cells, MSI2 is involved in post-transcriptional regulation by binding to the 3'-untranslated regions (3'-UTR) of target mRNAs, influencing their translation, stability, and turnover. This regulation is crucial for maintaining the balance between self-renewal and differentiation in stem cells (das2020Interplay).

MSI2 is expressed in various tissues, including bone marrow stromal cells (BMSCs), where it regulates the differentiation of these cells into osteoblasts and adipocytes. It promotes osteoblastogenesis while inhibiting adipogenesis by repressing the PPARγ signaling pathway, a major driver of adipocyte differentiation (Suo2022The). MSI2 achieves this by binding to the mRNA of Cebpα, a key adipogenic factor, thereby inhibiting its translation and reducing the expression of PPARγ (Suo2022The).

In the central nervous system, MSI2 is expressed in neural precursor cells and is thought to maintain specific neuronal lineages by regulating gene expression at the post-transcriptional level, potentially through mRNA stabilization or translational control (Sakakibara2001RNA-Binding). MSI2's activity in these processes is essential for maintaining the proliferative capacity of stem cells and ensuring proper cell differentiation and tissue homeostasis.

## Clinical Significance
Alterations in the expression of the MSI2 gene have been implicated in various cancers, often correlating with poor prognosis. In non-small cell lung cancer (NSCLC), MSI2 is significantly upregulated in metastatic cell lines and human tumors compared to normal lung tissue. This overexpression is associated with reduced overall survival and increased tumor metastasis, suggesting MSI2 as a potential therapeutic target (Kudinov2016Musashi2).

In mantle cell lymphoma (MCL), MSI2 expression is upregulated in cases with SOX11 overexpression, correlating with poor overall survival. MSI2 knockdown reduces tumor growth and dissemination, indicating its role in MCL pathogenesis (SuredaGómez2022Tumorigenic).

MSI2 is also overexpressed in colorectal cancer (CRC), where it promotes cell proliferation and tumor growth. Its activation mimics the loss of the APC tumor suppressor, contributing to early tumorigenesis (Wang2015Transformation).

In breast cancer, MSI2 is upregulated and associated with poor prognosis, particularly in HER2-negative cases. The DBC2 gene, a tumor suppressor, regulates MSI2 levels through ubiquitination, and loss of DBC2 leads to increased MSI2 expression (Choi2016DBC2RhoBTB2).

## Interactions
Musashi-2 (MSI2) is an RNA-binding protein that interacts with various proteins and nucleic acids, playing a significant role in post-transcriptional regulation. MSI2 is known to bind directly to the 3' untranslated regions (UTRs) of target mRNAs, influencing their translation and stability. In hematopoietic stem cells (HSCs), MSI2 interacts with components of the TGF-β signaling pathway, including TGFBR1 and SMAD3, modulating their translation and affecting cell fate and lineage bias (Park2014Musashi-2). MSI2's binding to these targets was validated through RNA immunoprecipitation experiments, highlighting its role in regulating quiescence and lineage determination (Park2014Musashi-2).

In non-small cell lung cancer (NSCLC), MSI2 supports TGF-β signaling by promoting the expression of TGFβR1 and SMAD3, which are involved in epithelial-mesenchymal transition (EMT). MSI2 depletion leads to increased expression of claudins, suggesting that MSI2 typically represses these proteins, thereby influencing cell-cell junctions and cancer cell invasiveness (Kudinov2016Musashi2). MSI2 also interacts with RNA molecules in triple-negative breast cancer (TNBC), where it binds to the 3′-UTRs of TP53INP1 mRNA, promoting its stability and affecting ERK signaling pathways (Li2020RNAbinding). These interactions underscore MSI2's complex regulatory roles in various cellular contexts.


## References


[1. (Sakakibara2001RNA-Binding) Shin-ichi Sakakibara, Yuki Nakamura, Hitoshi Satoh, and Hideyuki Okano. Rna-binding protein musashi2: developmentally regulated expression in neural precursor cells and subpopulations of neurons in mammalian cns. The Journal of Neuroscience, 21(20):8091–8107, October 2001. URL: http://dx.doi.org/10.1523/jneurosci.21-20-08091.2001, doi:10.1523/jneurosci.21-20-08091.2001. This article has 203 citations.](https://doi.org/10.1523/jneurosci.21-20-08091.2001)

[2. (SuredaGómez2022Tumorigenic) Marta Sureda-Gómez, Patricia Balsas, Marta-Leonor Rodríguez, Ferran Nadeu, Anna De Bolòs, Álvaro Eguileor, Marta Kulis, Giancarlo Castellano, Cristina López, Eva Giné, Santiago Demajo, Pedro Jares, José I. Martín-Subero, Silvia Beà, Elias Campo, and Virginia Amador. Tumorigenic role of musashi-2 in aggressive mantle cell lymphoma. Leukemia, 37(2):408–421, December 2022. URL: http://dx.doi.org/10.1038/s41375-022-01776-x, doi:10.1038/s41375-022-01776-x. This article has 4 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41375-022-01776-x)

[3. (das2020Interplay) Pablo Ferreira das Chagas, Mirella Baroni, María Sol Brassesco, and Luiz Gonzaga Tone. Interplay between the rna binding‐protein musashi and developmental signaling pathways. The Journal of Gene Medicine, January 2020. URL: http://dx.doi.org/10.1002/jgm.3136, doi:10.1002/jgm.3136. This article has 14 citations.](https://doi.org/10.1002/jgm.3136)

[4. (Kudinov2016Musashi2) Alexander E. Kudinov, Alexander Deneka, Anna S. Nikonova, Tim N. Beck, Young-Ho Ahn, Xin Liu, Cathleen F. Martinez, Fred A. Schultz, Samuel Reynolds, Dong-Hua Yang, Kathy Q. Cai, Khaled M. Yaghmour, Karmel A. Baker, Brian L. Egleston, Emmanuelle Nicolas, Adaeze Chikwem, Gregory Andrianov, Shelly Singh, Hossein Borghaei, Ilya G. Serebriiskii, Don L. Gibbons, Jonathan M. Kurie, Erica A. Golemis, and Yanis Boumber. Musashi-2 (msi2) supports tgf-β signaling and inhibits claudins to promote non-small cell lung cancer (nsclc) metastasis. Proceedings of the National Academy of Sciences, 113(25):6955–6960, June 2016. URL: http://dx.doi.org/10.1073/pnas.1513616113, doi:10.1073/pnas.1513616113. This article has 118 citations.](https://doi.org/10.1073/pnas.1513616113)

[5. (Li2020RNAbinding) Ming Li, An-qi Li, Shu-ling Zhou, Hong Lv, Ping Wei, and Wen-tao Yang. Rna-binding protein msi2 isoforms expression and regulation in progression of triple-negative breast cancer. Journal of Experimental &amp; Clinical Cancer Research, May 2020. URL: http://dx.doi.org/10.1186/s13046-020-01587-x, doi:10.1186/s13046-020-01587-x. This article has 28 citations.](https://doi.org/10.1186/s13046-020-01587-x)

[6. (Suo2022The) Jinlong Suo, Sihai Zou, Jinghui Wang, Yujiao Han, Lingli Zhang, Chenchen Lv, Bo Jiang, Qian Ren, Long Chen, Lele Yang, Ping Ji, Xianyou Zheng, Ping Hu, and Weiguo Zou. The rna-binding protein musashi2 governs osteoblast-adipocyte lineage commitment by suppressing pparγ signaling. Bone Research, March 2022. URL: http://dx.doi.org/10.1038/s41413-022-00202-3, doi:10.1038/s41413-022-00202-3. This article has 28 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41413-022-00202-3)

[7. (Choi2016DBC2RhoBTB2) Y M Choi, K B Kim, J H Lee, Y K Chun, I S An, S An, and S Bae. Dbc2/rhobtb2 functions as a tumor suppressor protein via musashi-2 ubiquitination in breast cancer. Oncogene, 36(20):2802–2812, December 2016. URL: http://dx.doi.org/10.1038/onc.2016.441, doi:10.1038/onc.2016.441. This article has 23 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2016.441)

[8. (Park2014Musashi-2) Sun-Mi Park, Raquel P. Deering, Yuheng Lu, Patrick Tivnan, Steve Lianoglou, Fatima Al-Shahrour, Benjamin L. Ebert, Nir Hacohen, Christina Leslie, George Q. Daley, Christopher J. Lengner, and Michael G. Kharas. Musashi-2 controls cell fate, lineage bias, and tgf-β signaling in hscs. Journal of Experimental Medicine, 211(1):71–87, January 2014. URL: http://dx.doi.org/10.1084/jem.20130736, doi:10.1084/jem.20130736. This article has 134 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1084/jem.20130736)

[9. (Wang2015Transformation) Shan Wang, Ning Li, Maryam Yousefi, Angela Nakauka-Ddamba, Fan Li, Kimberly Parada, Shilpa Rao, Gerard Minuesa, Yarden Katz, Brian D. Gregory, Michael G. Kharas, Zhengquan Yu, and Christopher J. Lengner. Transformation of the intestinal epithelium by the msi2 rna-binding protein. Nature Communications, March 2015. URL: http://dx.doi.org/10.1038/ncomms7517, doi:10.1038/ncomms7517. This article has 142 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms7517)